In a phase 1b/2 clinical trial, PM8002 showed an overall survival rate of 69.7% after 18 months in patients with breast cancer and a PD-L1 protein overexpression. Merck's Keytruda's survival rate ...

There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes an upfront $112 million licensing rights payment for ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Merck & Co. has secured a licensing agreement with Chinese drugmaker Hansoh Pharma for an experimental oral weight-loss drug, marking its latest foray into the burgeoning obesity treatment market. The ...

LaNova is also eligible to receive up to $2.7B in milestone payments associate Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to "market perform" from "outperform ...

Merck (NYSE:MRK) reported positive Phase 2 data from its waveLINE-007 trial evaluating its antibody drug conjugate zilovertamab vedotin in the treatment of diffuse large B-cell lymphoma ...

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million ...

Based on estimates for this year, Merck's earnings multiple is 13.2, and since the company is forecasted to show strong earnings per share growth in the coming years—between revenue growth ...